Update on new drugs in small cell lung cancer

Bibliography

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
   PubMed Web of Science ®Google Scholar
• Govindan R, Page N, Morgensztern D, Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-44
   PubMed Web of Science ®Google Scholar
• Elias AD. Small cell lung cancer: state-of-the-art therapy in 1996. Chest 1997;112:251S-258S
   PubMed Web of Science ®Google Scholar
• Simon GR, Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines. 2nd edition. Chest 2007;132:324S-339S
   PubMed Web of Science ®Google Scholar
• Clark R, Ihde DC. Small-cell lung cancer: treatment progress and prospects. Oncology (Williston Park) 1998;12:647-58; discussion 61-3
   PubMed Web of Science ®Google Scholar
• Johnson DH, Bass D, Einhorn LH, Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. J Clin Oncol 1993;11:1223-9
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Furuse K, Saijo N, Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991;83:855-61
   PubMed Web of Science ®Google Scholar
• Sundstrom S, Bremnes RM, Kaasa S, Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized Phase III trial with 5 years' follow-up. J Clin Oncol 2002;20:4665-72
   PubMed Web of Science ®Google Scholar
• Chute JP, Chen T, Feigal E, Twenty years of Phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-801
   PubMed Web of Science ®Google Scholar
• Roth BJ, Johnson DH, Einhorn LH, Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282-91
   PubMed Web of Science ®Google Scholar
• Feld R, Evans WK, Coy P, Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol 1987;5:1401-9
   PubMed Web of Science ®Google Scholar
• Evans WK, Feld R, Murray N, Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med 1987;107:451-8
   PubMed Web of Science ®Google Scholar
• Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000;83:8-15
   PubMed Web of Science ®Google Scholar
• Evans WK, Shepherd FA, Feld R, VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985;3:1471-7
   PubMed Web of Science ®Google Scholar
• Goodman GE, Crowley JJ, Blasko JC, Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study. J Clin Oncol 1990;8:39-47
   PubMed Web of Science ®Google Scholar
• Janne PA, Freidlin B, Saxman S, Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 2002;95:1528-38
   PubMed Web of Science ®Google Scholar
• Perez CA, Einhorn L, Oldham RK, Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report. J Clin Oncol 1984;2:1200-8
   PubMed Web of Science ®Google Scholar
• Ardizzoni A, Hansen H, Dombernowsky P, Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997;15:2090-6
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
   PubMed Web of Science ®Google Scholar
• Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991;22:339-47
   PubMedGoogle Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64
   PubMed Web of Science ®Google Scholar
• Macchiarini P, Fontanini G, Dulmet E, Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet. Ann Thorac Surg 1994;57:1534-9
   PubMed Web of Science ®Google Scholar
• Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-53
   PubMed Web of Science ®Google Scholar
• Yano T, Tanikawa S, Fujie T, Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur J Cancer 2000;36:601-9
   PubMed Web of Science ®Google Scholar
• Fontanini G, Lucchi M, Vignati S, Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997;89:881-6
   PubMed Web of Science ®Google Scholar
• Lucchi M, Mussi A, Fontanini G, Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardiothorac Surg 2002;21:1105-10
   PubMed Web of Science ®Google Scholar
• Horn L, Dahlberg SE, Sandler AB, Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009;27:6006-11
   PubMed Web of Science ®Google Scholar
• Ready N, Dudek AZ, Wang XF, CALGB 30306: a phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC). J Clin Oncol (ASCO meeting abstracts) 2007;25:7563
   Google Scholar
• Spigel DR, Hainsworth JD, Yardley DA, Phase II trial of irinotecan, carboplatin, and bevacizumab in patients with extensive-stage small cell lung cancer. Meeting abstracts. J Clin Oncol 2007;25:18130
   Google Scholar
• Patton JF, Spigel DR, Greco FA, Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by maintenance bevacizumab (B) in the treatment (tx) of limited-stage small cell lung cancer (LS-SCLC): update of a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol (ASCO meeting abstracts) 2006;24:7085
   Google Scholar
• Zubkus JD, Spigel DR, Greco FA, Phase II trial of irinotecan, carboplatin, and bevacizumab in patients with limited-stage small cell lung cancer. J Clin Oncol (ASCO meeting abstracts) 2007;25:18133
   Google Scholar
• Ramalingam SS, Mack PC, Vokes EE, Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): a California Consortium phase II study. Meeting abstracts. J Clin Oncol 2008;26:8078
   Google Scholar
• Heymach J, Glisson BS, Doebele RC, Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC). Meeting abstracts. J Clin Oncol 2010;28:7050
   Google Scholar
• Carlomagno F, Vitagliano D, Guida T, ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284-90
   PubMed Web of Science ®Google Scholar
• Wedge SR, Ogilvie DJ, Dukes M, ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-55
   PubMed Web of Science ®Google Scholar
• Arnold AM, Smylie M, Ding K, Randomized phase II study of maintenance vandetanib (ZD6474) in small cell lung cancer (SCLC) patients who have a complete or partial response to induction therapy: NCIC CTG BR.20. Meeting abstracts. J Clin Oncol 2007;25:7522
   Google Scholar
• Arnold AM, Seymour L, Smylie M, Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007;25:4278-84
   PubMed Web of Science ®Google Scholar
• Heymach J, Paz-Ares L, De Braud F, Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC). Meeting abstracts. J Clin Oncol 2007;25:7544
   Google Scholar
• Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 2007;5:203-20
   PubMed Web of Science ®Google Scholar
• Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004;10:6388S-63892S
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
   PubMed Web of Science ®Google Scholar
• Gitlitz BJ, Glisson BS, Moon J, Sorafenib in patients with platinum (plat) treated extensive stage small cell lung cancer (E-SCLC): a SWOG (S0435) phase II trial. J Clin Oncol (ASCO meeting abstracts) 2008;26:8039
   Google Scholar
• Abrams TJ, Lee LB, Murray LJ, SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-8
   PubMed Web of Science ®Google Scholar
• Ready N, Dunphy F, Pang H, Combination chemotherapy with sunitinib (IND 74019; NSC 736511) for untreated extensive-stage small cell lung cancer (SCLC): CALGB 30504 phase IB safety results. J Clin Oncol (ASCO meeting abstracts) 2010;28:7056
   Google Scholar
• Lubiner ET, Spigel DR, Greco FA, Phase II study of irinotecan and carboplatin followed by maintenance sunitinib in the first-line treatment of extensive-stage small cell lung cancer. J Clin Oncol (ASCO meeting abstracts). 2010;28:7049
   Google Scholar
• Schneider BJ, Gadgeel SM, Ramnath N, Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES SCLC). J Clin Oncol (ASCO meeting abstracts) 2010;28:e18041
   Google Scholar
• Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004;363:1802-11
   PubMed Web of Science ®Google Scholar
• D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5
   PubMed Web of Science ®Google Scholar
• Lee SM, James L, Buchler T, Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer. Lung Cancer 2008;59:364-8
   PubMed Web of Science ®Google Scholar
• Pujol JL, Breton JL, Gervais R, Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol 2007;25:3945-51
   PubMed Web of Science ®Google Scholar
• Lee S, Rudd M, Woll PJ. Two Randomised phase III, double blind placebo controlled trails in patients with advanced NSCLC and SCLC. J Clin Oncol (Meeting abstracts) 2008;26(15 Suppl):8045
   Google Scholar
• Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-49
   PubMed Web of Science ®Google Scholar
• Michael M, Babic B, Khokha R, Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 1999;17:1802-8
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Giaccone G, Seymour L, Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002;20:4434-9
   PubMed Web of Science ®Google Scholar
• Rigas JR, Denham CA, Rinaldi D, Randomized placebo-controlled trials of the matrix metalloproteinase inhibitor (MMPI), BAY 12-9566 as adjuvant therapy for patients with small cell and non-small cell lung cancer. Meeting abstracts. J Clin Oncol 2003;22:2525
   Google Scholar
• Janus A, Robak T, Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett 2005;10:479-98
   PubMed Web of Science ®Google Scholar
• Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48
   PubMed Web of Science ®Google Scholar
• Kraus AC, Ferber I, Bachmann SO, In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene 2002;21:8683-95
   PubMed Web of Science ®Google Scholar
• Krystal GW, Sulanke G, Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 2002;1:913-22
   PubMed Web of Science ®Google Scholar
• Pandya KJ, Dahlberg S, Hidalgo M, A randomized, Phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2007;2:1036-41
   PubMed Web of Science ®Google Scholar
• Schiller JH, Adak S, Cella D, Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593– A Phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:2114-22
   PubMed Web of Science ®Google Scholar
• Kotsakis AP, Tarhini A, Petro D, Phase II study of RAD001 (everolimus) in previously treated small cell lung cancer (SCLC). J Clin Oncol (ASCO meeting abstracts) 2009;27:8107
   Google Scholar
• Sekido Y, Obata Y, Ueda R, Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res 1991;51:2416-19
   PubMed Web of Science ®Google Scholar
• Potti A, Moazzam N, Ramar K, CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma. Ann Oncol 2003;14:894-7
   PubMed Web of Science ®Google Scholar
• Hibi K, Takahashi T, Sekido Y, Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 1991;6:2291-6
   PubMed Web of Science ®Google Scholar
• Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996;56:370-6
   PubMed Web of Science ®Google Scholar
• Naeem M, Dahiya M, Clark JI, Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. Hum Pathol 2002;33:1182-7
   PubMed Web of Science ®Google Scholar
• Micke P, Basrai M, Faldum A, Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res 2003;9:188-94
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Griffith DJ, Druker BJ, Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-32
   PubMed Web of Science ®Google Scholar
• Wang WL, Healy ME, Sattler M, Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 2000;19:3521-8
   PubMed Web of Science ®Google Scholar
• Krystal GW, Honsawek S, Litz J, Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000;6:3319-26
   PubMed Web of Science ®Google Scholar
• Johnson BE, Fischer T, Fischer B, Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003;9:5880-7
   PubMed Web of Science ®Google Scholar
• Krug LM, Crapanzano JP, Azzoli CG, Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a Phase II clinical trial. Cancer 2005;103:2128-31
   PubMed Web of Science ®Google Scholar
• Dy GK, Miller AA, Mandrekar SJ, A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005;16:1811-16
   PubMed Web of Science ®Google Scholar
• Johnson FM, Krug LM, Tran HT, Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma. Cancer 2006;106:366-74
   PubMed Web of Science ®Google Scholar
• Spigel DR, Hainsworth JD, Simons L, Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a Phase II trial of the Minnie Pearl Cancer Research Network. J Thorac Oncol 2007;2:854-61
   PubMed Web of Science ®Google Scholar
• Schneider BJ, Kalemkerian GP, Ramnath N, Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer. Clin Lung Cancer 2010;11:223-7
   PubMed Web of Science ®Google Scholar
• Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-37
   PubMed Web of Science ®Google Scholar
• Ikegaki N, Katsumata M, Minna J, Tsujimoto Y. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994;54:6-8
   PubMed Web of Science ®Google Scholar
• Campos L, Rouault JP, Sabido O, High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993;81:3091-6
   PubMed Web of Science ®Google Scholar
• Mortenson MM, Schlieman MG, Virudachalam S, Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer. Lung Cancer 2005;49:163-70
   PubMed Web of Science ®Google Scholar
• Dole M, Nunez G, Merchant AK, Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 1994;54:3253-9
   PubMed Web of Science ®Google Scholar
• Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 1998;78:1035-42
   PubMed Web of Science ®Google Scholar
• Rudin CM, Otterson GA, Mauer AM, A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 2002;13:539-45
   PubMed Web of Science ®Google Scholar
• Rudin CM, Kozloff M, Hoffman PC, Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 2004;22:1110-17
   PubMed Web of Science ®Google Scholar
• Rudin CM, Salgia R, Wang X, Randomized Phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008;26:870-6
   PubMed Web of Science ®Google Scholar
• Masuda N, Fukuoka M, Kusunoki Y, CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992;10:1225-9
   PubMed Web of Science ®Google Scholar
• Noda K, Nishiwaki Y, Kawahara M, Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91
   PubMed Web of Science ®Google Scholar
• Hanna N, Bunn PA Jr, Langer C, Randomized Phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-43
   PubMed Web of Science ®Google Scholar
• Natale RB, Lara PN, Chansky K, S0124: a randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC). J Clin Oncol (ASCO meeting abstracts) 2008;26:7512
   Google Scholar
• Schmittel A, Fischer von Weikersthal L, Sebastian M, A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol 2006;17:663-7
   PubMed Web of Science ®Google Scholar
• Chen G, Huynh M, Fehrenbacher L, Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol 2009;27:1401-4
   PubMed Web of Science ®Google Scholar
• Yamaoka T, Hanada M, Ichii S, Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 1998;89:1067-73
   PubMedGoogle Scholar
• Okamoto I, Hamada A, Matsunaga Y, Phase I dose-escalation and pharmacokinetic study of amrubicin in patients with recurrent advanced lung cancer. J Clin Oncol (ASCO meeting abstracts). 2005;23:2068
   Google Scholar
• Katakami N, Hata A, Yoshioka H, Phase I study of amrubicin (AMR) for patients (pts) with previously treated small cell lung cancer (SCLC). J Clin Oncol (ASCO meeting abstracts) 2007;25:18209
   Google Scholar
• Kato T, Nokihara H, Ohe Y, Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC). J Clin Oncol (ASCO meeting abstracts) 2006;24:7061
   Google Scholar
• Onoda S, Masuda N, Seto T, Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006;24:5448-53
   PubMed Web of Science ®Google Scholar
• Seto T, Masuda N, Takiguchi Y, Phase II study of amrubicin, a new active drug in refractory or relapsed small-cell lung cancer (SCLC): Thoracic Oncology Research Group Trial 0301. J Clin Oncol (ASCO meeting abstracts) 2006;24:7060
   Google Scholar
• Kudoh S, Yashimura N, Kimura T, A phase II trail of amrubicin (AMR) for recurrent or refractory small cell lung cancer (SCLC). J Clin Oncol (ASCO meeting abstracts) 2006;24(16 Suppl):17053
   Google Scholar
• von Pawel J, Schiller JH, Shepherd FA, Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-67
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Jotte RM, Gupta V, A phase II trail of single agent amrubicin (AMR) in patients with ED-SCLC that is refractory or progressive within 90 days of completion of first-line platinum based chemotheraphy. J Clin Oncol (ASCO meeting abstract) 2008;26(15 Suppl):8041
   Google Scholar
• Jotte RM, Conkling PR, Reynolds C, A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensive-disease small-cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy. J Clin Oncol (ASCO meeting abstracts) 2008;26:8040
   Google Scholar
• Ohe Y, Negoro S, Matsui K, Phase I–II study of amrubicin and cisplatin in previously untreated patients with extensive stage small cell lung cancer (ED-SCLC) (final report). J Clin Oncol (ASCO meeting abstracts) 2004;22:7206
   Google Scholar
• Fukuda M, Nakamura Y, Kasai T, A phase I study of amrubicin and carboplatin for previously untreated patients with extensive stage small-cell lung cancer. J Clin Oncol (ASCO meeting abstracts) 2008;26:19070
   Google Scholar
• Hirose T, Shirai T, Kusomoto S, Phase II study of amrubicin and carboplatin in patients with the refractory or relapsed small cell lung cancer (SCLC). J Clin Oncol (ASCO meeting abstracts) 2010;28:7057
   Google Scholar
• Inoue A, Ishimoto O, Fukumoto S, A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405. Ann Oncol 2010;21:800-3
   PubMed Web of Science ®Google Scholar
• Mio T, Kawahara M, Fukushima M, A phase I study of amrubicin (AMR) and irinotecan (CPT-11) in relapsed small cell lung cancer. J Clin Oncol (ASCO meeting abstracts) 2007;25:18181
   Google Scholar
• Kawahara M, Kubo A, Komuta K, A phase I study of amrubicin (AMR) and irinotecan (CPT-11) in relapsed small cell lung cancer(SCLC). J Clin Oncol (ASCO meeting abstracts) 2008;26:13548
   Google Scholar
• Lee JH, Lee SJ, Kim JS, Phase II trial of CKD-602, a new camptothecin analogue, in patients with small cell lung cancer (SCLC). J Clin Oncol (ASCO meeting abstracts) 2004;22:7210
   Google Scholar
• Lee DH, Kim SW, Suh C, Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. Ann Oncol 2008;19:123-7
   PubMed Web of Science ®Google Scholar
• Kim JW, Kim S, Kim SC, A phase II study of belotecan (CDK-602) camptobell in patients with SCLC. Chest 2006;130:232S-c
   Google Scholar
• Lee DH, Kim SW, Bae KS, A Phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer. Clin Cancer Res 2007;13:6182-6
   PubMed Web of Science ®Google Scholar
• Lee DH, Kim SW, Suh C, Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer. Cancer 2010;116:132-6
   PubMed Web of Science ®Google Scholar
• Dowlati A, Mekhail T, O'Brien T, Phase II trial of becatecarin (rebeccamycin analogue) in relapsed sensitive small cell lung cancer (SCLC). J Clin Oncol (ASCO meeting abstracts) 2008;26:19060
   Google Scholar
• Niemeyer CC, Bailey B, Reifert J, SDX-105 (bendamustine) is a clinically active chemotherapeutic agent with a distinct mechanism of action [abstract 1129]. AACR Meeting abstracts 2004
   Google Scholar
• Koster W, Stamatis G, Heider A, Carboplatin in combination with bendamustine in previously untreated patients with extensive-stage small cell lung cancer (SCLC). Clin Drug Investig 2004;24:611-18
   PubMed Web of Science ®Google Scholar
• Koster W, Heider A, Niederle N, Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer. J Thorac Oncol 2007;2:312-16
   PubMed Web of Science ®Google Scholar
• Koester W, Stamatis G, Niederle N, Phase-II-study with bendamustine / carboplatin in untreated patients with extensive disease small cell lung cancer. Meeting abstracts. J Clin Oncol 2004;22:7265
   Google Scholar
• Kawamura-Akiyama Y, Kusaba H, Kanzawa F, Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines. Lung Cancer 2002;38:43-50
   PubMed Web of Science ®Google Scholar
• Sharp SY, O'Neill CF, Rogers P, Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin. Eur J Cancer 2002;38:2309-15
   PubMed Web of Science ®Google Scholar
• Treat J, Schiller J, Quoix E, ZD0473 treatment in lung cancer: an overview of the clinical trial results. Eur J Cancer 2002;38(Suppl 8):S13-18
   PubMedGoogle Scholar
• Eckardt JR, Bentsion DL, Lipatov ON, Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol 2009;27:2046-51
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Samarzjia M, Demidchik Y, Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy. J Clin Oncol (ASCO meeting abstracts) 2010;28:7002
   Google Scholar
• Hanna N, Shepherd FA, Fossella FV, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97
   PubMed Web of Science ®Google Scholar
• Hanna NH, Ansari R, Bhatia S, Pemetrexed in patients (pts) with relapsed small cell lung cancer (SCLC): a phase II study from the Hoosier Oncology Group. J Clin Oncol (ASCO meeting abstracts) 2006;24:7063
   Google Scholar
• Gronberg BH, Bremnes RM, Aasebo U, A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer 2009;63:88-93
   PubMed Web of Science ®Google Scholar
• Socinski MA, Weissman C, Hart LL, Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol 2006;24:4840-7
   PubMed Web of Science ®Google Scholar
• Socinski MA, Smit EF, Lorigan P, Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol 2009;27:4787-92
   PubMed Web of Science ®Google Scholar
• Dowlati A, Subbiah S, Cooney M, Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. Lung Cancer 2007;56:377-81
   PubMed Web of Science ®Google Scholar
• Kocs DM, Raju RN, Socinski MA, Preliminary results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (ENZ) versus docetaxel (D) + Cb as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol (ASCO meeting abstracts) 2008;26:8061
   Google Scholar